FIRAZYR General Drug Use-Results Survey (Japan)

Shire

Status: Completed

Conditions: Hereditary Angioedema (HAE)

Treatments: Drug: Firazyr

Study type: Observational

Funder types: Industry

Identifiers

NCT04057131

SHP667-401

Details and patient eligibility

About

The objectives of this survey are to collect data to report the safety and efficacy of Firazyr (Icatibant acetate) in the post-marketing phase in participants diagnosed with Hereditary Angioedema (HAE).

Enrollment: 179 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• Hereditary angioedema (HAE) participants in Japan who receive FIRAZYR for first time in the real world clinical setting.

Exclusion Criteria

Trial design

179 participants in 1 patient group

Firazyr

Description:

Participants with Hereditary angioedema (HAE) receiving treatment with Icatibant acetate (Firazyr) as prescribed by their physician following locally approved prescribing information.

Treatment:

Drug: Firazyr